Wird geladen...

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s ma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Hematol Oncol
Hauptverfasser: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784459/
https://ncbi.nlm.nih.gov/pubmed/26957112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0250-9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!